EXINI Diagnostics AB
EXINI launching a new website about the imaging biomarker Bone Scan Index
DGAP-News: EXINI Diagnostics AB / 18.12.2013 / 14:27 --------------------------------------------------------------------- Lund, Sweden, 2013-12-18 14:27 CET (GLOBE NEWSWIRE) -- Bone Scan Index (BSI) has attracted great interest by offering new possibilities within cancer care. A new website http://bonescanindex.org is now being launched. The website contains all the available documentation, information and knowledge about BSI. 'Bone Scan Index (BSI) and our program EXINI boneBSI have raised considerable interest among clinicians and pharmaceutical companies. Now they can easily get access to all the information through the website, and thus make faster decisions on how to use BSI in clinical practice and in clinical trials' says Magnus Aurell, CEO EXINI Diagnostics AB. EXINI has in their software EXINI boneBSI developed a unique feature that automatically calculates the Bone Scan Index (BSI), a so-called imaging biomarker. BSI has in scientific studies proved to be highly beneficial in the monitoring and prognostication in patients with prostate cancer with metastatic disease to the bone. For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 18.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden ISIN: SE0001810284 End of News DGAP News-Service --------------------------------------------------------------------- 245375 18.12.2013
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden